Redeye previews Sleep Cycle ahead of its Q3 2026 report on 23 October. We lift our net sales estimate by c.1% to c.SEK50m. That implies the first sequential sales increase since Q4 2024: partner revenue from Ultrahuman, Moera and Ant Group offsets a subscriber decline that is now slowing. Reported EBIT is cut to a loss of c.SEK7m because we now book c.SEK14m in one-off costs: c.SEK7m for the CEO's departure and c.SEK7m for the September reorganisation. Adjusted EBIT stays at c.SEK6m.
LÄS MER
